Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
May 11 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, provides an update on recently presented
preclinical data demonstrating the anti-cancer potential of their
Lm vector that presents tumor neoantigens, and is being evaluated
in the ADXS-NEO program. ADXS-NEO is derived from the Company’s
proprietary Lm Technology and is being developed in partnership
with Amgen.
These preclinical findings were discussed in poster
presentations at the recent American Association for Cancer
Research (AACR) Annual Meeting. Additionally, portions of these
data were presented by Amgen at a podium presentation during the
European Neoantigen Summit 2018.
The first study, as discussed in a poster presentation at AACR
entitled “Neoantigens that fail to elicit measurable T cell
responses following peptide immunization can control tumor growth
when delivered using a Listeria-based immunotherapy platform,”
showed that ADXS-NEO generates T cell responses against neoantigen
peptides that control tumor growth, even when they were identified
as “non-immunogenic” using a conventional peptide-adjuvant
immunization. The poster is available here:
https://www.advaxis.com/wp-content/uploads/2018/05/ADXS-NEO-Lm-immunogenicity-AACR-poster_Final.pdf.
In the second study, discussed in a poster presentation at AACR
entitled “Targeting frameshift mutations with a Listeria
monocytogenes immunotherapy drives neoantigen-specific antitumor
immunity in MC38 and CT26 mouse tumor models,” Advaxis’ Lm platform
was shown to target frameshift mutations and generate T cells to
multiple neoantigens per frameshift in MC38 and CT26 mouse tumor
models. The poster is available here:
https://www.advaxis.com/wp-content/uploads/2018/05/ADXS-NEO-Lm-Frameshift-muations-AACR-poster_Final.pdf.
“The results of these studies highlight the therapeutic
potential of targeting neoantigens and suggest that ADXS-NEO could
impact the way we approach treatment across a range of cancers,”
said Ken Berlin, President and CEO of Advaxis. “We look forward to
our continued collaboration with Amgen, and to moving into the
clinic with this product candidate.”
“These preclinical findings provide foundational rationale
suggesting that ADXS-NEO has the potential to generate immune
responses against multiple neoantigens with the ability to control
tumor growth. This is a personalized approach that uses a patient’s
own immune system to recognize and eliminate cancer cells harboring
multiple mutations that caused their malignancy,” said Robert G.
Petit, Ph.D., Chief Scientific Officer and Executive Vice President
of Advaxis. “We also saw potent immune responses targeting
frameshift mutations and control of tumor growth via multiple
complementary mechanisms. This is important because frameshift
mutations are observed to generate up to nine times more
neoantigens per mutation than in-frame mutations” according to
Turajlic, et al.
About ADXS-NEO
ADXS-NEO is a personalized Listeria monocytogenes (Lm)-based
immunotherapy designed to generate immune response against
mutation-derived tumor-specific neoantigens. The program focuses on
creating a customized treatment with neoantigens specifically
selected based on a biopsy of the patient’s tumor. The approach
enables the development of tailored immune-therapies. ADXS-NEO is
being evaluated in collaboration with Amgen.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot/
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended January
31, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180511005134/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorInvestors:LHA Investor
RelationsMiriam Weber Miller, 212-838-3777mmiller@lhai.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024